Canada markets open in 3 hours 47 minutes

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1200+0.0200 (+1.82%)
At close: 04:00PM EST
1.1500 +0.03 (+2.68%)
Pre-Market: 05:14AM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe

    Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD DeficiencyApplied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net sales in Europe Deal strengthens Applied Therapeutics’ capital position and extends cash runway through key milestones NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-sta

  • GlobeNewswire

    Applied Therapeutics Reports Third Quarter 2022 Financial Results

    NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C

  • GlobeNewswire

    Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

    Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical